30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Peter Greenleaf

Track

Insider profile

Currently holds positions in Sucampo Pharmaceuticals Inc, Aurinia Pharmaceuticals Inc, BioDelivery Sciences International Inc, Antares Pharma Inc and Medimmune LLC

Performance

Overall performance
2.5
Performance over holding periods
2.5
30 days 90 days 120 days
Average return 24% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
1 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chairman of the Board, Chief Executive Officer Sucampo Pharmaceuticals Inc Jan. 1, 2016 -
Chief Executive Officer, Director Aurinia Pharmaceuticals Inc April 29, 2019 -
Independent Chairman of the Board BioDelivery Sciences International Inc May 1, 2018 -
Independent Director Antares Pharma Inc Dec. 12, 2018 -
President Medimmune LLC Feb. 1, 2010 -
Director Avalo Therapeutics Inc April 15, 2019 - Feb. 14, 2020
Director EyeGate Pharmaceuticals Inc July 10, 2018 - Jan. 3, 2020
Chief Executive Officer, Director Avalo Therapeutics Inc March 28, 2018 - April 15, 2019
Director Avalo Therapeutics Inc May 15, 2017 - March 28, 2018
Independent Director Synlogic Inc March 1, 2016 - Aug. 28, 2017
Independent Director Savara Inc Nov. 5, 2015 - April 27, 2017
Chief Executive Officer, Director Sucampo Pharmaceuticals Inc March 3, 2014 - Jan. 1, 2016
President, Chief Executive Officer, Director Ocugen Inc June 10, 2013 - Feb. 28, 2014
Peter Greenleaf's trades of Aurinia Pharmaceuticals Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-11 2026-05-11
PrS Proposed sale
74,408
13.46
US$1,699,673 		74,408 13.46 US$1,699,673
2026-04-06 2026-04-02
PlS Planned sale
90,668 +3.5%
68.84
US$4,258,095 		90,668 +3.5% 68.84 US$4,258,095
2026-04-06 2026-04-02
PlS Planned sale
37,968 -15.4%
208.95
US$3,303,850 		37,968 -15.4% 208.95 US$3,303,850
2025-03-04 2025-03-04
S Sale
164,947 -8.4%
7.92
US$1,306,380 		164,947 -8.4% 7.92 US$1,306,380
2025-03-04 2025-03-03
S Sale
195,593 -9.1%
8.00
US$1,564,744 		195,593 -9.1% 8.00 US$1,564,744
2024-03-07 2024-03-06
S Sale
126,981 -7.7%
5.60
US$711,094 		126,981 -7.7% 5.60 US$711,094
2023-03-06 2023-03-02
S Sale
32,750 -3.2%
8.94
US$292,785 		32,750 -3.2% 8.94 US$292,785
2022-03-04 2022-03-02
S Sale
9,068 -21.6%
12.01
US$108,907 		9,068 -21.6% 12.01 US$108,907
2018-05-21 2018-05-18
B Purchase
12,500 +3.1%
3.98
US$49,750 		12,500 +3.1% 3.98 US$49,750